Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Robert, Caroline; Karaszewska, Bogusława; Schachter, Jacob; Rutkowski, Piotr; Maćkiewicz, Andrzej; Stroiakovski, D.; Lichinitser, M.; Dummer, Reinhard; Grange, Florent; Mortier, Laurent; Chiarion‐Sileni, Vanna; Drucis, Kamil; Krajsová, Ivana; Hauschild, Axel; Lorigan, Paul; Wolter, Pascal; V. Long, Georgina; T. Flaherty, Keith; Nathan, Paul; Ribas, Antoni; Martin, Anne-Marie; Sun, Peng; Crist, Wendy; Legos, Jeff; D. Rubin, Stephen; M Little, Shonda; Schadendorf, Dirk

doi:10.1056/nejmoa1412690

Public

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Published in New England Journal of Medicine • Nov 16, 2014

Authors:

Caroline Robert

Bogusława Karaszewska

Jacob Schachter

Abstract

BACKGROUND: The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor a...

Subject

Dabrafenib

Vemurafenib

Trametinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!